1. Signaling Pathways
  2. JAK/STAT Signaling
  3. Pim
  4. PIM2 Isoform

PIM2

 

PIM2 Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-101870B
    Uzansertib phosphate
    Inhibitor 98.44%
    Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively.
  • HY-N4149
    Quercetagetin
    Inhibitor 99.74%
    Quercetagetin (6-Hydroxyquercetin) is a flavonoid.
  • HY-120758
    SEL24-B489
    Inhibitor 98.58%
    SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
  • HY-111552
    PIM1-IN-1
    Inhibitor 99.51%
    PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM.
  • HY-122665
    HTH-01-091
    Inhibitor
    HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM.
  • HY-123983
    HS56
    Inhibitor
    HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and >100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively.
  • HY-16576A
    (Z)-SMI-4a
    Inhibitor
    (Z)-SMI-4a is a poten, selective, cell-permeable and ATP-competitive Pim-1 inhibitor with an IC50 of 24 μM and a Ki of 0.6 µM.
  • HY-101783
    GNE-955
    Inhibitor
    GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.
  • HY-101870
    Uzansertib
    Inhibitor
    Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively.
  • HY-142696
    CDK6/PIM1-IN-1
    Inhibitor
    CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively.